| Q36120749 | A comparison of multiscale methods for the analysis of molecular dynamics simulations |
| Q30704432 | A fast method for predicting amino acid mutations that lead to unfolding. |
| Q37415505 | A global suppressor motif for p53 cancer mutants |
| Q34333807 | A novel p53 phosphorylation site within the MDM2 ubiquitination signal: II. a model in which phosphorylation at SER269 induces a mutant conformation to p53 |
| Q24530763 | A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants |
| Q96019130 | A rapid solubility assay of protein domain misfolding for pathogenicity assessment of rare DNA sequence variants |
| Q78477022 | A split-ubiquitin-based assay detects the influence of mutations on the conformational stability of the p53 DNA binding domain in vivo |
| Q39458140 | A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain |
| Q37236272 | Aggregation tendencies in the p53 family are modulated by backbone hydrogen bonds |
| Q30868722 | Allosteric drugs: thinking outside the active-site box. |
| Q33865095 | Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation |
| Q52558518 | Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines. |
| Q37210555 | An in silico algorithm for identifying stabilizing pockets in proteins: test case, the Y220C mutant of the p53 tumor suppressor protein |
| Q49481527 | An in silico approach in predicting the possible mechanism involving restoration of wild-type p53 functions by small molecular weight compounds in tumor cells expressing R273H mutant p53. |
| Q34570100 | Assessing TP53 status in human tumours to evaluate clinical outcome |
| Q35014385 | Awakening guardian angels: drugging the p53 pathway |
| Q51564147 | Binding of Rad51 and other peptide sequences to a promiscuous, highly electrostatic binding site in p53. |
| Q36009999 | Bioinformatics and variability in drug response: a protein structural perspective |
| Q24800091 | CP-31398, a putative p53-stabilizing molecule tested in mammalian cells and in yeast for its effects on p53 transcriptional activity |
| Q34036925 | CRINEPT-TROSY NMR reveals p53 core domain bound in an unfolded form to the chaperone Hsp90. |
| Q35946185 | Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides. |
| Q57778801 | Change of Conformation of the DNA-binding Domain of p53 Is the Only Key Element for Binding of and Interference with p73 |
| Q57838458 | Characterisation of the BRCT Domains of the Breast Cancer Susceptibility Gene Product BRCA1 |
| Q43955939 | Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. |
| Q37162374 | Chemopreventive effects of the p53-modulating agents CP-31398 and Prima-1 in tobacco carcinogen-induced lung tumorigenesis in A/J mice |
| Q83227500 | Computational and cellular studies reveal structural destabilization and degradation of MLH1 variants in Lynch syndrome |
| Q24628577 | Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53 |
| Q38787249 | Constitutive Activation of DNA Damage Checkpoint Signaling Contributes to Mutant p53 Accumulation via Modulation of p53 Ubiquitination |
| Q27642314 | Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations |
| Q21030644 | Determining biophysical protein stability in lysates by a fast proteolysis assay, FASTpp |
| Q34443272 | Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence. |
| Q39007874 | Distinct Rayleigh scattering from hot spot mutant p53 proteins reveals cancer cells |
| Q58615488 | Dynamics and Molecular Mechanisms of p53 Transcriptional Activation |
| Q45023386 | Effect of Y220C mutation on p53 and its rescue mechanism: a computer chemistry approach |
| Q51186530 | Effects of common cancer mutations on stability and DNA binding of full-length p53 compared with isolated core domains. |
| Q51151705 | Effects of oncogenic mutations and DNA response elements on the binding of p53 to p53-binding protein 2 (53BP2). |
| Q39809467 | Effects of stability on the biological function of p53. |
| Q34081676 | Effects of temperature on the p53-DNA binding interactions and their dynamical behavior: comparing the wild type to the R248Q mutant. |
| Q26822552 | Electrochemistry of nonconjugated proteins and glycoproteins. Toward sensors for biomedicine and glycomics |
| Q34058079 | Ensemble-based computational approach discriminates functional activity of p53 cancer and rescue mutants |
| Q36492803 | Evaluating Drosophila p53 as a model system for studying cancer mutations |
| Q40242926 | Exploiting Transient Protein States for the Design of Small-Molecule Stabilizers of Mutant p53. |
| Q34965167 | Expression of galectin-7 is induced in breast cancer cells by mutant p53. |
| Q35861153 | FUSE Binding Protein 1 Facilitates Persistent Hepatitis C Virus Replication in Hepatoma Cells by Regulating Tumor Suppressor p53. |
| Q30682940 | Factors governing loss and rescue of DNA binding upon single and double mutations in the p53 core domain |
| Q36187348 | First-order rate-determining aggregation mechanism of p53 and its implications |
| Q33325589 | Flexible nets: disorder and induced fit in the associations of p53 and 14-3-3 with their partners |
| Q43043487 | Folding and misfolding mechanisms of the p53 DNA binding domain at physiological temperature |
| Q41468886 | Folding of a cyclin box: linking multitarget binding to marginal stability, oligomerization, and aggregation of the retinoblastoma tumor suppressor AB pocket domain |
| Q89782502 | Follow the Mutations: Toward Class-Specific, Small-Molecule Reactivation of p53 |
| Q47616875 | From mutational inactivation to aberrant gain-of-function: Unraveling the structural basis of mutant p53 oncogenic transition |
| Q37808312 | From peptides to proteins: lessons from my years at the Centre for Protein Engineering |
| Q41832274 | Functional census of mutation sequence spaces: the example of p53 cancer rescue mutants. |
| Q32178579 | Fusaric Acid Induces DNA Damage and Post-Translational Modifications of p53 in Human Hepatocellular Carcinoma (HepG2 ) Cells. |
| Q34968621 | Fuse binding protein antagonizes the transcription activity of tumor suppressor protein p53. |
| Q57670523 | Gain of function of mutant p53 by coaggregation with multiple tumor suppressors |
| Q28068551 | Gain of function of mutant p53: R282W on the peak? |
| Q27678152 | Halogen-Enriched Fragment Libraries as Leads for Drug Rescue of Mutant p53 |
| Q35181268 | Halogen-enriched fragment libraries as chemical probes for harnessing halogen bonding in fragment-based lead discovery |
| Q43690426 | High thermostability and lack of cooperative DNA binding distinguish the p63 core domain from the homologous tumor suppressor p53. |
| Q34287510 | Highly adaptable triple-negative breast cancer cells as a functional model for testing anticancer agents |
| Q84551753 | Hsp70 molecular chaperones are required to support p53 tumor suppressor activity under stress conditions |
| Q28553055 | Hydrogen Bond Dynamic Propensity Studies for Protein Binding and Drug Design |
| Q59126521 | Impact of structural prior knowledge in SNV prediction: Towards causal variant finding in rare disease |
| Q51026030 | In vitro folding and characterization of the p53 DNA binding domain. |
| Q38418659 | Induction of nuclear translocation of mutant cytoplasmic p53 by geranylgeranoic acid in a human hepatoma cell line |
| Q37473855 | Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats |
| Q28000133 | Interaction of p53 with the CCT complex promotes protein folding and wild-type p53 activity |
| Q27667399 | Interaction of the p53 DNA-Binding Domain with Its N-Terminal Extension Modulates the Stability of the p53 Tetramer |
| Q35844807 | Investigating DNA Binding and Conformational Variation in Temperature Sensitive p53 Cancer Mutants Using QM-MM Simulations. |
| Q99712014 | Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy |
| Q58322007 | Kinetic Instability of p53 Core Domain Mutants |
| Q36187316 | Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition |
| Q35134797 | Mechanism of initiation of aggregation of p53 revealed by Φ-value analysis |
| Q42410745 | Molecular dynamics simulations of p53 DNA-binding domain |
| Q42088517 | Molecular mechanisms of functional rescue mediated by P53 tumor suppressor mutations |
| Q40002181 | Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature |
| Q41677793 | Multisite aggregation of p53 and implications for drug rescue |
| Q36689074 | Mutant p53 induces EZH2 expression and promotes epithelial-mesenchymal transition by disrupting p68-Drosha complex assembly and attenuating miR-26a processing |
| Q26770576 | Mutant p53: One, No One, and One Hundred Thousand |
| Q27334558 | Mutational Landscapes of Sequential Prostate Metastases and Matched Patient Derived Xenografts during Enzalutamide Therapy |
| Q53623512 | Mutational analysis of the p53 core domain L1 loop. |
| Q74631439 | NMR spectroscopy reveals the solution dimerization interface of p53 core domains bound to their consensus DNA |
| Q47673940 | Natural (and Unnatural) Small Molecules as Pharmacological Chaperones and Inhibitors in Cancer. |
| Q46268031 | Nimbolide reduces CD44 positive cell population and induces mitochondrial apoptosis in pancreatic cancer cells |
| Q80194726 | Nm23-H1/NDP kinase folding intermediates and cancer: a hypothesis |
| Q38723653 | Nuclear inclusion bodies of mutant and wild-type p53 in cancer: a hallmark of p53 inactivation and proteostasis remodelling by p53 aggregation. |
| Q92940029 | Oncogenic Gain of Function in Glioblastoma Is Linked to Mutant p53 Amyloid Oligomers |
| Q24796697 | PDBSite: a database of the 3D structure of protein functional sites |
| Q33909288 | Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases |
| Q38948352 | Peptides and peptidomimetics in the p53/MDM2/MDM4 circuitry - a patent review |
| Q50014672 | Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases |
| Q35134517 | Propagation of aggregated p53: Cross-reaction and coaggregation vs. seeding |
| Q44145204 | QM-MM simulations on p53-DNA complex: a study of hot spot and rescue mutants |
| Q50797771 | R248Q mutation--Beyond p53-DNA binding. |
| Q35750128 | RNA polymerase III transcription and cancer |
| Q74355214 | RNA polymerase III transcription can be derepressed by oncogenes or mutations that compromise p53 function in tumours and Li-Fraumeni syndrome |
| Q26800059 | Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer |
| Q36777373 | Reactivation of mutant p53: molecular mechanisms and therapeutic potential |
| Q58322012 | Recognition of DNA by p53 Core Domain and Location of Intermolecular Contacts of Cooperative Binding |
| Q37088668 | Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide |
| Q30329984 | Rescuing the function of mutant p53. |
| Q93095094 | Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses |
| Q73446293 | Resistance to DNA-damaging agents is discordant from experimental metastatic capacity in MEF ras-transformants-expressing gain of function MTp53 |
| Q31041084 | Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. |
| Q36710840 | Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. |
| Q30951237 | Reversible aggregation plays a crucial role on the folding landscape of p53 core domain |
| Q39205536 | Reviving the guardian of the genome: Small molecule activators of p53. |
| Q33795918 | SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53 |
| Q38774417 | SDM: a server for predicting effects of mutations on protein stability |
| Q36159205 | Simul-seq: combined DNA and RNA sequencing for whole-genome and transcriptome profiling |
| Q64231035 | Simulations of mutant p53 DNA binding domains reveal a novel druggable pocket |
| Q27677872 | Small molecule induced reactivation of mutant p53 in cancer cells |
| Q34619139 | Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism |
| Q50441463 | Spectroscopic studies on the irreversible heat-induced structural transition of Pin1 |
| Q27655864 | Stabilising the DNA-binding domain of p53 by rational design of its hydrophobic core |
| Q34462386 | Stability of p53 homologs |
| Q33322204 | Stability of the core domain of p53: insights from computer simulations |
| Q41453979 | Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding |
| Q35213967 | Stem cell biology and neurodegenerative disease |
| Q34076012 | Strategies for manipulating the p53 pathway in the treatment of human cancer. |
| Q27671671 | Structural Basis for ASPP2 Recognition by the Tumor Suppressor p73 |
| Q42138244 | Structural and functional implications of p53 missense cancer mutations |
| Q53251211 | Structural assessment of single amino acid mutations: application to TP53 function. |
| Q35127734 | Structural basis for understanding oncogenic p53 mutations and designing rescue drugs |
| Q36786022 | Structural biology of the tumor suppressor p53 and cancer-associated mutants |
| Q35051686 | Structural effects of the L145Q, V157F, and R282W cancer-associated mutations in the p53 DNA-binding core domain |
| Q27004001 | Structural insights into the transcription-independent apoptotic pathway of p53 |
| Q26830644 | Structure and apoptotic function of p73 |
| Q34579681 | Structure-based predictions broadly link transcription factor mutations to gene expression changes in cancers |
| Q36777367 | Structure-function-rescue: the diverse nature of common p53 cancer mutants |
| Q27680171 | Structures of oncogenic, suppressor and rescued p53 core-domain variants: mechanisms of mutant p53 rescue |
| Q45259201 | Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations |
| Q37002735 | Suppression of familial adenomatous polyposis by CP-31398, a TP53 modulator, in APCmin/+ mice |
| Q35531853 | Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore |
| Q36825602 | TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy |
| Q33685392 | TP53 mutations in human cancers: origins, consequences, and clinical use |
| Q27651295 | Targeted rescue of a destabilized mutant of p53 by an in silico screened drug |
| Q47291772 | Targeting mutant p53 for efficient cancer therapy. |
| Q33655329 | Targeting p53 for Novel Anticancer Therapy |
| Q52322370 | The Crystal Structure of the R280K Mutant of Human p53 Explains the Loss of DNA Binding. |
| Q27683709 | The DNA-binding domain mediates both nuclear and cytosolic functions of p53 |
| Q59526203 | The UMD TP53 database and website: update and revisions |
| Q37808944 | The missing Zinc: p53 misfolding and cancer |
| Q50999703 | The mutational status of p53 can influence its recognition by human T-cells. |
| Q39962118 | The novel p53 isoform "delta p53" is a misfolded protein and does not bind the p21 promoter site |
| Q33594094 | The p53 core domain is a molten globule at low pH: functional implications of a partially unfolded structure. |
| Q29617535 | The p53 pathway: positive and negative feedback loops |
| Q27686765 | The rebel angel: mutant p53 as the driving oncogene in breast cancer |
| Q35083487 | The stability of myocilin olfactomedin domain variants provides new insight into glaucoma as a protein misfolding disorder |
| Q37762069 | The tumor suppressor p53: from structures to drug discovery |
| Q36436698 | Transcriptional regulation by p53: one protein, many possibilities |
| Q35708113 | Translational approaches targeting the p53 pathway for anti-cancer therapy |
| Q37318326 | Ultraslow oligomerization equilibria of p53 and its implications |
| Q41844622 | Understanding pathogenic single-nucleotide polymorphisms in multidomain proteins--studies of isolated domains are not enough |
| Q51185198 | Using model proteins to quantify the effects of pathogenic mutations in Ig-like proteins. |
| Q64101707 | Wild type p53 function in p53 mutant harboring cells by treatment with Ashwagandha derived anticancer withanolides: bioinformatics and experimental evidence |
| Q58789576 | Wild-type p53 oligomerizes more efficiently than p53 hot-spot mutants and overcomes mutant p53 gain-of-function via a "dominant-positive" mechanism |
| Q28485288 | Wrapping effects within a proposed function-rescue strategy for the Y220C oncogenic mutation of protein p53 |
| Q55471290 | Zinc Metallochaperones as Mutant p53 Reactivators: A New Paradigm in Cancer Therapeutics. |
| Q41877619 | mCSM: predicting the effects of mutations in proteins using graph-based signatures. |
| Q33988333 | p53 Interacts with RNA polymerase II through its core domain and impairs Pol II processivity in vivo |
| Q58702684 | p53 Isoforms and Their Implications in Cancer |
| Q34153187 | p53 contains large unstructured regions in its native state |
| Q34498550 | p53 in head and neck cancer: functional consequences and environmental implications of TP53 mutations |
| Q61988945 | p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements |
| Q45876572 | p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay |
| Q44499462 | p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study |
| Q89783061 | p53's Extended Reach: The Mutant p53 Secretome |